Galecto Inc. (NASDAQ: GLTO)
$0.57
-0.0240 ( -4.06% ) 131.0K
Galecto Inc is a clinical-stage biotechnology company developing therapeutics designed to target the biological processes that lie at the heart of fibrosis and impact a broad range of fibrotic and related diseases, including cancer. Its initial focus is on the development of small-molecule inhibitors of galectin-3 and lysyl oxidase-like 2, or LOXL2. Its product candidate GB0139 is for the treatment of severe fibrotic lung diseases such as idiopathic pulmonary fibrosis, or IPF, a life-threatening progressive fibrotic disease of the lung. Its product GB1211, a selective oral galectin-3 inhibitor for the treatment of fibrosis related to non-alcoholic steatohepatitis, or NASH, and GB2064, a selective oral inhibitor of LOXL2 that it initially plans to develop for the treatment of myelofibrosis.
Market Data
Open
$0.57
Previous close
$0.59
Volume
131.0K
Market cap
$15.45M
Day range
$0.55 - $0.61
52 week range
$0.46 - $3.70
SEC Fillings
Form Type | Description | Pages | Date |
---|---|---|---|
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
8-k | 8K-related | 11 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
4 | Insider transactions | 1 | Jun 21, 2024 |
10-q | Quarterly Reports | 62 | Apr 29, 2024 |
def | Proxies and info statements | 5 | Apr 29, 2024 |
pre | Proxies and info statements | 5 | Apr 16, 2024 |
8-k | 8K-related | 11 | Mar 26, 2024 |